Pharm-Olam’s Response to COVID-19: Safety, Community, Research
The coronavirus (COVID-19) was recently declared a pandemic by the World Health Organization (WHO), and countries around the world are working to flatten their infection curve and forestall the transmission of this dangerous virus. At Pharm-Olam, we understand the impact that infectious diseases can have on individuals and communities, and we want to express our empathy to those who have been impacted. We are also doing our part to help reduce disease transmission while continuing to support research and the fight against infectious diseases like COVID-19.
This is a global crisis, and we are in it together.
Pharm-Olam is doing its part to keep everything moving and everyone safe.
We are writing to make you aware of the precautions we are taking to protect our staff as well as our patients, their families, and the communities where people live and work. We also want to assure you that we are doing our part to limit the progression of the coronavirus pandemic while continuing to manage our clinical studies in active new drug research.
Continuity of Work
Pharm-Olam has converted to a virtual work environment.
At this point, the vast majority of our staff have converted to a remote work format. Robust telecommunication technologies have allowed our team to work remotely without interrupting the necessary services we provide. This virtual working methodology has also allowed us to respect the social distancing protocols set in place by WHO.
Health and Safety
Protecting our employees and our patients is our priority.
All of our staff are now following the pandemic protocols issued by the World Health Organization, their local country guidelines as well as the recently released guidances from the FDA, MHRA, as they relate to the management of clinical trials. As medical and scientific professionals, Pharm-Olam has always maintained the highest standards of safety and data integrity. However, we also understand the importance of extra vigilance at this time and have issued further guidance to our employees. These guidelines include how we should now work differently with our investigative sites, vendors to do all that we can to provide for the safety of our patients while also protecting the integrity of our clinical trial conduct.
Only essential business travel is now permitted. Virtual platforms are in place to ensure communication between staff, sponsors, and sites during this difficult time.
Travel is being impacted globally, with most non-essential travel being severely restricted. As you might expect, many sites are also limiting or cancelling all monitoring visits. To manage this situation, we are actively working with our investigators and sponsors to put in place remote monitoring solutions.
Pharm-Olam is committed to you and your research.
We understand the concerns you will have regarding the continued conduct of your trial to the expected assumptions of even just a few weeks ago. We are committed to keeping you fully informed of our actions. We will be directly communicating the impacts of any change to study timelines, risks, and mitigations with all of our sponsors.
Clinical research is a journey. We go the distance to help you create a healthier world.
Pharm-Olam understands the challenge that navigating a global pandemic presents, and we are committed to finding new ways to collaborate that limits the risk of virus transmission. While we navigate these uncharted waters, please know that we are dedicated to this journey and that we will go the extra distance to help you create a healthier world.
If you have any questions or concerns, please reach out to your account manager, study manager or contact us via our website, or click here.
Chief Executive Officer
About Rob Davie
Dr. Robert Davie joined Pharm-Olam in October 2019 as Chief Executive Officer. In this role, he leads Pharm-Olam's global workforce and business strategies supporting phase I-IV drug development programs for our biotech and pharmaceutical clients. Prior to joining Pharm-Olam, Dr. Davie worked at Covance, Inc. as Vice President and General Manager, Global Clinical Development. In this role, he was responsible for the oversight and delivery of clinical operations in more than 60 countries and with more than 6,000 staff under his leadership. Prior to joining Covance, Rob Worked at Procter & Gamble in OTC Healthcare in the clinical management of a number of different therapeutic areas. His experience includes registration, MOA and marketing studies. Rob began his career in basic science, particularly in GI physiology studying metal ion transport, and the transport of bile acids in patients with inflammatory bowel disease. Rob holds a bachelor’s degree from the University of Wolverhampton and a PhD in gastrointestinal absorption from the Council for National Academic Awards in the UK.
- Connect with Rob Davie